LEXINGTON, Mass., June 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of various cancers, today announced the issuance of U.S. Patent No. 8,461,157, which claims methods of treating human diseases or disorders mediated by one or more of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and histone deacetylase (HDAC) proteins, using compounds from a genus of small molecules with dual inhibitory properties, including but not limited to CUDC-907, a proprietary clinical stage dual inhibitor of PI3K and HDAC enzymes. This patent, along with another related patent issued in February 2013 (U.S. Patent No. 8,367,663), significantly enhances the intellectual property portfolio for Curis' proprietary chemical entities that target PI3K and HDAC, and in some instances mTOR, within a single molecule for the treatment of certain human diseases.
"We believe that this patent issuance significantly bolsters the intellectual property protection for Curis' proprietary dual targeted inhibitory molecules, including CUDC-907, a molecule that was invented by Curis scientists and is currently in Phase I clinical testing in patients with relapsed or refractory lymphomas or multiple myeloma," stated Dan Passeri, Curis' Chief Executive Officer. "As we continue to advance this current Phase I study, we are also planning to initiate additional studies with CUDC-907 in solid tumors later this year."
About CUDC-907CUDC-907 is a dual inhibitor of the Class I PI3K, as well as Class I and II HDAC subtypes. Specifically, CUDC-907 is designed to inhibit PI3K-alpha, delta and beta isoforms and HDACs 1, 2, 3, 6 and 10, the combined inhibition of which Curis believes has synergistic effects against cancer cells and their microenvironment. In preclinical studies, CUDC-907 has demonstrated the ability to suppress multiple nodes of cellular survival and proliferation signaling pathways. In addition, preclinical data have shown that CUDC-907 inhibits compensatory pathways that are often utilized in cancer cells during the emergence of resistance to standard-of-care agents.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts